Subasumstat by Takeda Pharmaceutical for Relapsed Multiple Myeloma: Likelihood of Approval

Subasumstat is under clinical development by Takeda Pharmaceutical and currently in Phase II for Relapsed Multiple Myeloma.

Socioeconomic status shapes the gut microbiome in diverse U.S. population

Study using data from the FAMiLI project reveals socioeconomic status (SES) significantly impacts the gut microbiome’s diversity and composition across a diverse U.S. population, underscoring

March 14, 2024

New research affirms clozapine safety with minimal blood cancer risk

An inter-departmental research team at the LKS Faculty of Medicine of the University of Hong Kong (HKUMed) has conducted the world’s first analytic real-world cohort

January 2, 2025

Medicare slashes safety net hospital payments on estimate that more people have insurance

The federal government will pay hospitals that treat poor and uninsured patients almost $1 billion less next year, a cut that’s more than eight times

August 4, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.